A key driver for the market's growth is the rising incidence of complex diseases, particularly cancer. Companion diagnostics are essential in oncology, where they are used to identify specific genetic mutations or biomarkers in a patient's tumor. This information allows clinicians to select the most effective targeted therapies, avoiding a one-size-fits-all approach that often leads to ineffective treatment and unnecessary costs. The co-development of drugs and their corresponding CDx tests ensures that a reliable diagnostic tool is available at the time of drug approval. https://www.marketresearchfutu....re.com/reports/compa
